Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Exercise plus amino acids may trim fat in metabolic syndrome

NCT ID NCT01326416

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study looked at whether a program of physical exercise combined with a daily supplement of leucine and arginine could help obese adults with metabolic syndrome lose body fat and improve their health. About 79 participants took part. The goal was to see if this approach could reduce fat mass and improve related health measures like blood pressure and blood sugar.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

79 people

The number who actually took part.

Start date

Mar 2011

Finished

Nov 2015

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 55 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Suffering from obesity (Body Mass Index (BMI) \> 30kg.m-2) with a maximal weight of 135 kg * Suffering from metabolic syndrome (International Federation of Diabetes(FID) definition) * Hospitalized or followed in consultation * Age 18 to 55 years old * Not having recently participated in other clinical studies during the last days before pre-inclusion consultation * Affiliated to a National Insurance scheme * Having National Social Security insurance Exclusion Criteria: * Asthma, chronic respiratory failure, obstructive chronic bronchitis * Current or recent Pneumothorax, recent pleural draining or biopsy, current hemoptysis, untreated / in course of treatment active tuberculosis * Coronaropathy, myocardiopathy, myocarditis, unstable cardiac failure, ventricular rhythm disorders * Severe Anemia * Severe inferior members Arteritis * Incapacity to walk or cycle * Severe renal failure (Creatinine Clearance \<or = 30 mL/min) * Severe Sepsis * Psychiatric Disorders (Diagnostic and Statistical Manual - Revision 4 (DSM IV) criteria) such as schizophrenia, other psychoses or major depressive non treated syndromes * Severe or non treated Eating Disorders implicated in obesity (compulsive access, bulimia) * Patients under guardianship or with curators * Women in age of procreation without means of effective contraception * Pregnant or breast-feeding women * Taking medicates such as: proteinate powder (Protifar ®, SP95 ®, Orlistat (Xenical ®, Ally ®), exenatide (Byetta ®), sitagliptin (Januvia ®, Xelevia ®), vildagliptin (Galvus ®), sitagliptin-metformin (Janumet ®), Vildagliptin-metformin (Eucreas ®), tadalafil (Cialis ®) sildenafil (Viagra ®) * Drug addiction to opiates in the last six months * Alcohol or drug abuse * Infection by Human Immunodeficiency Virus (HIV) , viral hepatitis B and viral hepatitis C * Active addiction to smoking in more than 8 cigarettes a day * Understanding badly spoken or written French * Performed, in 2 to 3 days preceding the Dual-energy X-Ray Absorptiometry (DEXA) exam, of a bone scintigraphy or a digestive tract radiological examination with the use of barium type of contrast agent.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Metabolic syndrome are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • University Hospital of Rouen

    Rouen, 76031, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.